Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

Sponsor
Seoul National University Bundang Hospital
Study ID
NCT02338921
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Sitagliptin — DRUG
    100mg qd per oral during 24months compared with other treatment groups
  • Dapagliflozin — DRUG
    10mg qd per oral during 24months compared with other treatment groups
  • Lobeglitazone — DRUG
    0.5mg qd per oral during 24months compared with other treatment groups
  • Glimepirde — DRUG
  • Metformin — DRUG

Study Details

To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and metformin.

Key Dates

Start date
Jan 31, 2015
Status verified
Jan 2022
Primary completion
Nov 30, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
78 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Glimepirde, Metformin, Sitagliptin
    Dipeptidyl peptidase-4 (DPP4) inhibitor Sitagliptin
  • Active Comparator: Glimepirde, Metformin, Dapagliflozin
    Sodium-glucose cotransporter 2 (SGLT2) inhibitors Dapagliflozin
  • Active Comparator: Glimepirde, Metformin, Lobeglitazone
    Peroxisome proliferator-activated receptor gamma agonist Lobeglitazone

Primary Outcome Measure

Glycemic target goal achievement rate [ Time Frame: 24 months ]

Related Studies